staceywhite, Author at European Medical Journal - Page 119 of 194

This site is intended for healthcare professionals

Continue
8 Mins
31 Oct 2017

Session One: Basal Insulins: Still Innovating After All These Years

Advances in understanding diabetes pathophysiology and treatment permit individualised therapy based on patient-centred treatment plans.
1 Mins
31 Oct 2017

A Role for Connexin Mediated Cell Communication in Fibrosis of Tubular Epithelial Cells in the Diabetic Kidney

Diabetic nephropathy represents the leading cause of end-stage renal disease and is the greatest cause of patient entry into the renal replacement…
2 Mins
31 Oct 2017

Sex Differences in the Diabetes-Associated Risk of Cardiovascular Events in a Young Population

The diabetes-associated excess risk of cardiovascular diseases is known to be higher in women than in men. Find out more in the article
12 Mins
31 Oct 2017

Session Two: Changing the Type 2 Diabetes Mellitus Management Paradigm with Fixed-Ratio Combinations

Fixed-ratio combinations, the co-administration of two injectable therapies in a formulation that can be adjusted through titration, are changing the…
2 Mins
31 Oct 2017

Short-Term Renal Effects of Vildagliptin Addition and Their Clinical and Laboratory Predictors in Insulin-Treated Type 2 Diabetes Mellitus Patients: A Randomised, Comparative, Prospective Clinical Study

Positive renal effects of vildagliptin have been shown by several experimental studies.1,2 Nonetheless, clinical evidence for its renoprotective…
19 Mins
31 Oct 2017

Session Three: Innovating Beyond Glucose Control in Diabetes Care

Advances in treatment offerings are moving beyond classical considerations around glucose control to focus on other aspects of the disease.
2 Mins
31 Oct 2017

Acute Endothelial Benefits of Fat Restriction Over Carbohydrate Restriction in Type 2 Diabetes Mellitus

The current ‘Western cluster’ of non-communicable disorders could be redefined as a dysfunction of the heterogenic, complex, and bidirectional metabolic…
10 Mins
31 Oct 2017

Editor’s Pick: Addressing Hypertension in the Patient with Type 2 Diabetes Mellitus: Pathogenesis, Goals, and Therapeutic Approach

Hypertension is considered a powerful cardiovascular risk factor and is present in up to two-thirds of patients who suffer from diabetes. In the…
10 Mins
31 Oct 2017

Future Treatments of Diabetic Retinopathy: Pharmacotherapeutic Products Under Development

Diabetic macular oedema (DMO) is the leading cause of vision loss in working aged individuals. Macular laser photocoagulation was the primary DMO…
2 Mins
31 Oct 2017

Duration-8 Randomised Controlled Trial 1-Year Results: Efficacy and Safety of Once-Weekly Exenatide Plus Once-Daily Dapagliflozin Versus Exenatide or Dapagliflozin Alone

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors have complementary mechanisms of action.
We’ve noticed you’re accessing
from North/South America.